Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5883066 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 5 Pages |
Abstract
Our results, except for the prevalence of acute promyelocytic leukemia, are concordant with those reported in the literature with approximately 35% of the patients cytogenetically normal. Testing patients with normal karyotype for other molecular markers such as CCAAT/enhancer-binding protein alpha mutations, isocitrate dehydrogenase 1/2 mutations, and mixed lineage leukemia rearrangements could therefore provide additional prognostic, predictive, and therapeutic values for AML patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Layal El Halabi, Isabelle Djaffar-Jureidini, Noha Hakime, Ghada Saidy, Nabil Chamseddine,